Craig R Lee
Overview
Explore the profile of Craig R Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
3099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fashe M, Miner T, Collazo V, Grieco J, Fallon J, Jackson K, et al.
Drug Metab Dispos
. 2025 Mar;
53(2):100025.
PMID: 40023573
Cytochrome P450 (CYP) 3A4 is an essential drug-metabolizing enzyme in humans, which shows substantial interindividual variation in response to various intrinsic and extrinsic factors such as sex and pregnancy. In...
2.
Fashe M, Tiley J, Lee C
Expert Opin Drug Metab Toxicol
. 2025 Feb;
:1-18.
PMID: 39992297
Introduction: Pregnancy alters the systemic exposure and clearance of many hepatically cleared drugs that are commonly used by obstetric patients. Understanding the molecular mechanisms underlying the changes in factors that...
3.
Ainslie K, Bowers A, Chichewicz R, Collier L, Doorn J, Frei C, et al.
AAPS J
. 2025 Feb;
27(1):41.
PMID: 39904863
On October 29, 2024, a virtual meeting, brought together chairs and vice chairs from several research-oriented U.S. Schools of Pharmacy to discuss the current landscape of pharmaceutical sciences, advocacy strategies,...
4.
Tunehag K, Pearce A, Fox L, Stouffer G, Solander S, Lee C
Clin Transl Sci
. 2025 Jan;
18(1):e70131.
PMID: 39822142
In neurovascular settings, including treatment and prevention of ischemic stroke and prevention of thromboembolic complications after percutaneous neurointerventional procedures, dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the...
5.
Cavallari L, Hicks J, Patel J, Elchynski A, Smith D, Bargal S, et al.
Pharmacogenet Genomics
. 2024 Nov;
35(1):1-11.
PMID: 39485373
Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual's genotype in conjunction with other important clinical factors. Despite significant evidence of genetic...
6.
Fox L, Tunehag K, Nguyen A, Reed S, Shastri D, Quig N, et al.
Pharmacogenomics
. 2024 Oct;
25(12-13):503-513.
PMID: 39360670
To evaluate the feasibility and impact of using genotype to guide selection of antiplatelet therapy in patients undergoing intracranial aneurysm treatment with a flow diversion stent in a real-world clinical...
7.
van den Broek W, Ingraham B, Pereira N, Lee C, Cavallari L, Swen J, et al.
J Am Coll Cardiol
. 2024 Sep;
84(12):1107-1118.
PMID: 39260933
The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a...
8.
Shao D, Mosha J, Patel R, Lee C, Stouffer G
Cardiovasc Drugs Ther
. 2024 Sep;
38(6):1079-1081.
PMID: 39230622
No abstract available.
9.
Cavallari L, Lee C, Franchi F, Keeley E, Rossi J, Thomas C, et al.
Clin Transl Sci
. 2024 Aug;
17(8):e70004.
PMID: 39150361
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Approximately...
10.
AlSaeed M, Thomas C, Franchi F, Keeley E, Duarte J, Gong Y, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1227-1230.
PMID: 39031256
The ABCD-GENE score was developed to predict poor response to clopidogrel and includes Age, Body mass index, Chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m),...